Anika Therapeutics Announces New Date for Third Quarter Conference Call.Business Editors WOBURN, Mass.--(BUSINESS WIRE)--Nov. 1, 2000 Anika Therapeutics, Inc. (Nasdaq:ANIK ANIK Canadian COMSAT ) today announced that reporting of third quarter 2000 results has been rescheduled to Monday, Nov. 13, 2000. The company plans to host a conference call at 11 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy that same day to discuss the quarter's results with shareholders and investors. Those interested in listening to the call should dial 888/740-9683. A replay of the call will be available from 1:30 p.m. EST Monday, Nov. 13, through midnight Monday, Nov. 20. To listen to the recorded call dial 800/633-8284, access code 16746376. About Anika Therapeutics Anika Therapeutics, Inc. (www.anikatherapeutics.com) develops, manufactures and commercializes therapeutic products and devices intended to promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible biocompatible /bio·com·pat·i·ble/ (-kom-pat´i-b'l) being harmonious with life; not having toxic or injurious effects on biological function. polymer found throughout the body. In addition to ORTHOVISC(R), a treatment for osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. of the knee (not approved for sale in the U.S.), Anika markets HYVISC(R) in the U.S. for the treatment of equine osteoarthritis through Boehringer Ingelheim Vetmedica, Inc. and manufactures Amvisc(R) and Amvisc(R) Plus, HA viscoelastic Adj. 1. viscoelastic - having viscous as well as elastic properties natural philosophy, physics - the science of matter and energy and their interactions; "his favorite subject was physics" products for ophthalmic surgery, for Bausch & Lomb Surgical. Therapies currently under development include INCERT(R), a family of HA products designed to prevent post-surgical adhesions. Anika is also collaborating with Orquest, Inc. to manufacture OSSIGEL(R), an injectable formulation of basic fibroblast growth factor Basic fibroblast growth factor, also known as bFGF or FGF2, is a member of the fibroblast growth factor family. In normal tissue, basic fibroblast growth factor is present in basement membranes and in the subendothelial extracellular matrix of blood combined with HA designed to accelerate the healing of bone fractures, which is also under development. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion